First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six ...

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.

At Axtria Ignite 2025 in Princeton, New Jersey, editor-in-chief Jonah Comstock connected with GSK's SVP of enterprise AI and chief digital and technology officer, commercial, Madhavi Ramakrishna.

The global Musculoskeletal Oncology Therapeutics Market is projected to grow from USD 2.2 billion in 2025 to USD 3.3 billion ...

Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.03 ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

KNOWING where to invest your cash is difficult as there are thousands of companies to choose from. That’s why Holly Mead, a ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

Indian equities fell on August 12, with the Nifty 50 down 0.40% and the S&P BSE Sensex down 0.46%. Investors were cautious ahead of US inflation data, which could influence the Federal Reserve's ...